Drug (ID: DG00308) and It's Reported Resistant Information
Name
Ampicillin
Synonyms
ABPC; Acillin; Adobacillin; Alpen; Amblosin; Amcill; Amfipen; Aminobenzylpenicillin; Ampen; Ampichel; Ampicil; Ampicilina; Ampicillanyl; Ampicillina; Ampicilline; Ampicillinum; Ampicin; Ampifarm; Ampikel; Ampimed; Ampipenin; Ampiscel; Ampisyn; Ampivax; Ampivet; Amplacilina; Amplin; Amplipenyl; Amplisom; Amplital; Austrapen; Binotal; Bonapicillin; Britacil; Campicillin; Cimex; Copharcilin; Delcillin; Deripen; Divercillin; Doktacillin; Duphacillin; Grampenil; Guicitrina; Guicitrine; Lifeampil; Morepen; Norobrittin; Nuvapen; Omnipen; Orbicilina; Penbristol; Penbritin; Penbrock; Penicline; Penimic; Pensyn; Pentrex; Pentrexl; Pentrexyl; Polycillin; Ponecil; Princillin; Principen; QIDamp; Racenacillin; Rosampline;Roscillin; Semicillin; Servicillin; Sumipanto; Supen; Synpenin; Texcillin; Tokiocillin; Tolomol; Totacillin; Totalciclina; Totapen; Trifacilina; Ukapen; Ultrabion; Ultrabron; Vampen; Viccillin; Wypicil; Amfipen V; Amipenix S; Ampicillin A; Ampicillin Anhydrous; Ampicillin Base; Ampicillin acid; Ampicillin anhydrate; Ampicillina [DCIT]; Anhydrous ampicillin; Olin Kid; Pen A; Pen A Oral; Pen Ampil;Penbritin paediatric; Penbritin syrup; Pfizerpen A; Semicillin R; Viccillin S; AY 6108; BA 7305; BRL 1341; Bayer 5427; HI 63; P 50; Principen 125; Principen 250; Principen 500; SQ 17382; AB-PC; AB-PCSol; AY-6108; Ambidrin (TN); Ampi-Co; Ampi-Tab; Ampi-bol; Ampicilina [INN-Spanish]; Ampicilline [INN-French]; Ampicillinum [INN-Latin]; Ampipenin, nt3; Ampy-Penyl; Anhydrous ampicillin (JP15); BRL-1341; D-Ampicillin; D-Cillin; KS-R1; Novo-ampicillin; OMNIPEN (AMPICILLIN); Omnipen (TN); Omnipen-N; P-50; Penbritin-S; Penicillin, Aminobenzyl; Pfizerpen-A; Polycillin-N; Polyflex (Veterinary); Ro-Ampen; SK-Ampicillin; Totacillin (sodium); Totacillin-N; WY-5103; Ampicillin (USP/INN); AMPICILLIN (SEE ALSO AMPICILLIN TRIHYDRATE 7177-48-2); Ampicillin [USAN:BAN:INN:JAN]; Ampicillin [USAN:INN:BAN:JAN];D-(-)-Ampicillin; D-(-)-alpha-Aminobenzylpenicillin; D-(-)-alpha-Aminopenicillin; D-(-)-6-(alpha-Aminophenylacetamido)penicillanic acid; 6-(D(-)-alpha-Aminophenylacetamido)penicillanic acid; 6beta-[(2R)-2-amino-2-phenylacetamido]-2,2-dimethylpenam-3alpha-carbonyl; 6beta-[(2R)-2-amino-2-phenylacetamido]-2,2-dimethylpenam-3alpha-carboxylic acid
    Click to Show/Hide
Indication
In total 1 Indication(s)
Bacterial infection [ICD-11: 1A00-1C4Z]
Approved
[1], [2]
Structure
Drug Resistance Disease(s)
Disease(s) with Clinically Reported Resistance for This Drug (11 diseases)
Bacterial infection [ICD-11: 1A00-1C4Z]
[3]
Cholera [ICD-11: 1A00]
[4]
Escherichia coli intestinal infection [ICD-11: 1A03]
[3]
Non-tuberculous mycobacteria infection [ICD-11: 1B21]
[5]
Peritonitis [ICD-11: DC50]
[6]
Pharyngitis [ICD-11: CA02]
[7]
Pneumonia [ICD-11: CA40]
[8]
Shigellosis [ICD-11: 1A02]
[9]
Tissue pyogenic bacterial infection [ICD-11: 1B7Y]
[10]
Ulcer [ICD-11: EH90]
[5]
Urinary tract infection [ICD-11: GC08]
[11]
Disease(s) with Resistance Information Validated by in-vivo Model for This Drug (2 diseases)
Escherichia coli intestinal infection [ICD-11: 1A03]
[12]
Periodontal disease [ICD-11: DA0C]
[13]
Target Bacterial Penicillin binding protein (Bact PBP) NOUNIPROTAC [1]
Click to Show/Hide the Molecular Information and External Link(s) of This Drug
Formula
C16H19N3O4S
IsoSMILES
CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)C(=O)O)C
InChI
1S/C16H19N3O4S/c1-16(2)11(15(22)23)19-13(21)10(14(19)24-16)18-12(20)9(17)8-6-4-3-5-7-8/h3-7,9-11,14H,17H2,1-2H3,(H,18,20)(H,22,23)/t9-,10-,11+,14-/m1/s1
InChIKey
AVKUERGKIZMTKX-NJBDSQKTSA-N
PubChem CID
6249
ChEBI ID
CHEBI:28971
TTD Drug ID
D0YA9Z
VARIDT ID
DR00712
INTEDE ID
DR2177
DrugBank ID
DB00415
Type(s) of Resistant Mechanism of This Drug
  DISM: Drug Inactivation by Structure Modification
  IDUE: Irregularity in Drug Uptake and Drug Efflux
  UAPP: Unusual Activation of Pro-survival Pathway
Drug Resistance Data Categorized by Their Corresponding Diseases
ICD-01: Infectious/parasitic diseases
Click to Show/Hide the Resistance Disease of This Class
Cholera [ICD-11: 1A00]
Click to Show/Hide
Drug Resistance Data Categorized by Their Corresponding Mechanisms
       Drug Inactivation by Structure Modification (DISM) Click to Show/Hide
Key Molecule: Erythromycin esterase (EREA2) [4]
Molecule Alteration Expression
Inherence
Resistant Disease Vibrio cholerae infection [ICD-11: 1A00.0]
Experimental Note Identified from the Human Clinical Data
In Vitro Model Vibrio cholerae PG153/1 666
Vibrio cholerae PG170 666
Vibrio cholerae PL96 666
Experiment for
Molecule Alteration
PCR and DNA sequencing assay
Experiment for
Drug Resistance
Commercial antimicrobial discs assay
Mechanism Description The expression of dfrA5, ereA2 lead to drug resistance.
       Unusual Activation of Pro-survival Pathway (UAPP) Click to Show/Hide
Key Molecule: Aminoglycoside (3'') (9) adenylyltransferase (AADA) [4]
Molecule Alteration Expression
Inherence
Resistant Disease Vibrio cholerae infection [ICD-11: 1A00.0]
Experimental Note Identified from the Human Clinical Data
In Vitro Model Vibrio cholerae O26 strain AS482 567107
Vibrio cholerae O39 strain AS634 666
Experiment for
Molecule Alteration
PCR and DNA sequencing assay
Experiment for
Drug Resistance
Commercial antimicrobial discs assay
Mechanism Description The expression of aadA1-S lead to drug resistance.
Key Molecule: Dihydrofolate reductase (DHFR) [4]
Molecule Alteration Expression
Inherence
Resistant Disease Vibrio cholerae infection [ICD-11: 1A00.0]
Experimental Note Identified from the Human Clinical Data
In Vitro Model Vibrio cholerae O62 strain AS438 666
Vibrio cholerae PG149a 666
Vibrio cholerae PG224 666
Vibrio cholerae PG262(b) 666
Vibrio cholerae PG9 666
Vibrio cholerae PG95 666
Vibrio cholerae PL1 666
Vibrio cholerae PL61 666
Vibrio cholerae PL78/6 666
Vibrio cholerae PL91 666
Vibrio cholerae PG92 666
Experiment for
Molecule Alteration
PCR and DNA sequencing assay
Experiment for
Drug Resistance
Commercial antimicrobial discs assay
Mechanism Description The expression of dfrA1 lead to drug resistance.
Key Molecule: Dihydrofolate reductase (DHFR) [4]
Molecule Alteration Expression
Inherence
Resistant Disease Vibrio cholerae infection [ICD-11: 1A00.0]
Experimental Note Identified from the Human Clinical Data
In Vitro Model Vibrio cholerae PG153/1 666
Vibrio cholerae PG170 666
Vibrio cholerae PL96 666
Experiment for
Molecule Alteration
PCR and DNA sequencing assay
Experiment for
Drug Resistance
Commercial antimicrobial discs assay
Mechanism Description The expression of dfrA15 lead to drug resistance.
Bacterial infection [ICD-11: 1A00-1C4Z]
Click to Show/Hide
Drug Resistance Data Categorized by Their Corresponding Mechanisms
       Drug Inactivation by Structure Modification (DISM) Click to Show/Hide
Key Molecule: Beta-lactamase (BLA) [1], [2]
Molecule Alteration Expression
Up-regulation
Resistant Disease Bacterial infection [ICD-11: 1A00-1C4Z]
Experimental Note Identified from the Human Clinical Data
In Vitro Model Mycobacterium tuberculosis H37Rv 83332
Escherichia coli DH10B 316385
Mycobacterium smegmatis PM274 1772
Mycobacterium smegmatis PM759 1772
Mycobacterium smegmatis PM791 1772
Mycobacterium smegmatis PM876 1772
Mycobacterium smegmatis PM939 1772
Mycobacterium smegmatis PM976 1772
Mycobacterium tuberculosis PM638 1773
Mycobacterium tuberculosis PM669 1773
Mycobacterium tuberculosis PM670 1773
Experiment for
Molecule Alteration
Whole genome sequence assay
Experiment for
Drug Resistance
Disk diffusion test assay; E-strip test assay
Mechanism Description Mycobacteria produce Beta-lactamases and are intrinsically resistant to Beta-lactam antibiotics.The mutants M. tuberculosis PM638 (detablaC1) and M. smegmatis PM759 (detablaS1) showed an increase in susceptibility to Beta-lactam antibiotics.
Key Molecule: Beta-lactamase (BLA) [14], [15]
Molecule Alteration Expression
Up-regulation
Resistant Disease Bacterial infection [ICD-11: 1A00-1C4Z]
Experimental Note Identified from the Human Clinical Data
In Vitro Model Escherichia coli HB101 634468
Escherichia coli JM101 562
Experiment for
Molecule Alteration
Whole genome sequence assay
Mechanism Description Beta-lactamases (Beta-lactamhydrolase, EC 3.5.2.6), responsible for most of the resistance to Beta-lactam antibiotics, are often plasmid mediated.The OXA-1 beta-lactamase gene is part of Tn2603, which is borne on the R plasmid RGN238.
Key Molecule: Beta-lactamase (BLA) [15], [16], [17]
Molecule Alteration Missense mutation
p.L76N+p.V84I+p.A184V
Resistant Disease Bacterial infection [ICD-11: 1A00-1C4Z]
Experimental Note Identified from the Human Clinical Data
In Vitro Model Escherichia coli JM109 562
Mechanism Description The TEM Beta-lactamases are among the best-studied antibiotic resistance enzymes around.TEM-1, the first TEM allele identified, was isolated from penicillin-resistant bacteria in 1963.
Key Molecule: Beta-lactamase (BLA) [15], [16], [17]
Molecule Alteration Missense mutation
p.L76N
Resistant Disease Bacterial infection [ICD-11: 1A00-1C4Z]
Experimental Note Identified from the Human Clinical Data
In Vitro Model Escherichia coli JM109 562
Mechanism Description The TEM Beta-lactamases are among the best-studied antibiotic resistance enzymes around.TEM-1, the first TEM allele identified, was isolated from penicillin-resistant bacteria in 1963.
Key Molecule: Beta-lactamase (BLA) [18]
Molecule Alteration Expression
Inherence
Resistant Disease Pseudomonas aeruginosa infection [ICD-11: 1A00-1C4Z]
Experimental Note Identified from the Human Clinical Data
In Vitro Model Pseudomonas aeruginosa PAO1 208964
Experiment for
Molecule Alteration
DNA sequencing and protein assay
Experiment for
Drug Resistance
Disk diffusion assay
Mechanism Description P. aeruginosa harbors two naturally encoded Beta-lactamase genes, one of which encodes an inducible cephalosporinase and the other of which encodes a constitutively expressed oxacillinase. OXA-50 is a kind of oxacillinase which lead to drug resistance.
Key Molecule: Aminoglycoside acetyltransferase (AAC) [19]
Molecule Alteration Expression
Inherence
Resistant Disease Vibrio fluvialis infection [ICD-11: 1A00-1C4Z]
Experimental Note Identified from the Human Clinical Data
In Vitro Model Vibrio fluvialis H-08942 676
Experiment for
Molecule Alteration
PCR; DNA sequencing assay; Southern hybridization assay; Cloning and expression assay
Experiment for
Drug Resistance
Broth microdilution method assay
Mechanism Description Aac(3)-Id is a new type of aminoglycoside acetyltransferase gene which causes drug resistance.
Key Molecule: Metallo-beta-lactamase (VIM1) [3]
Molecule Alteration Expression
Inherence
Resistant Disease Achromobacter xylosoxydans infection [ICD-11: 1A00-1C4Z]
Experimental Note Identified from the Human Clinical Data
In Vitro Model Escherichia coli 668369
Achromobacter xylosoxydans subsp. denitrificans AX-22 85698
Escherichia coli MkD-135 562
Pseudomonas aeruginosa 10145/3 287
Experiment for
Molecule Alteration
DNA extraction and Sequencing assay
Experiment for
Drug Resistance
Macrodilution broth method assay
Mechanism Description A. xylosoxydans AX22 exhibited broad-spectrum resistance to Beta-lactams and aminoglycosides. The Beta-lactam resistance pattern (including piperacillin, ceftazidime, and carbapenem resistance) was unusual for this species, and the high-level carbapenem resistance suggested the production of an acquired carbapenemase. In fact, carbapenemase activity was detected in a crude extract of AX22 (specific activity, 184 +/- 12 U/mg of protein), and this activity was reduced (>80%) after incubation of the crude extract with 2 mM EDTA, suggesting the presence of a metallo-Beta-lactamase determinant.
Key Molecule: Beta-lactamase (BLA) [15], [20]
Molecule Alteration Missense mutation
p.V77A+p.D114N+p.S140A+p.N288D
Resistant Disease Bacterial infection [ICD-11: 1A00-1C4Z]
Experimental Note Identified from the Human Clinical Data
In Vitro Model Citrobacter freundii strain 2524/96 546
Citrobacter freundii strain 2525/96 546
Citrobacter freundii strain 2526/96 546
Escherichia coli strain 2527/96 562
Experiment for
Drug Resistance
Agar dilution method assay
Mechanism Description Sequencing has revealed that C. freundii isolates produced a new CTX-M-3 enzyme which is very closely related to the CTX-M-1/MEN-1 Beta-lactamase.
Key Molecule: Imipenem-hydrolyzing beta-lactamase (NMCA) [21]
Molecule Alteration Expression
Inherence
Resistant Disease Enterobacter cloacae infection [ICD-11: 1A00-1C4Z]
Experimental Note Identified from the Human Clinical Data
In Vitro Model Escherichia coli strain JM109 83333
Enterobacter cloacae strain NOR-1 550
Experiment for
Molecule Alteration
Dideoxynucleotide chain-termination method assay
Experiment for
Drug Resistance
MIC assay
Mechanism Description Here we report a gene encoding a carbapenemase, which was cloned from the chromosome of a clinical isolate of Enterobacter cloacae, strain NOR-1, into pACYC184 plasmid in Escherichia coli. Unlike all the sequenced carbapenemases, which are class B metallo-beta-lactamases, the mature protein (NmcA) is a class A serine beta-lactamase. NmcA shares the highest amino acid identity (50%) with the extended-spectrum class A beta-lactamase MEN-1 from Escherichia coli.
       Irregularity in Drug Uptake and Drug Efflux (IDUE) Click to Show/Hide
Key Molecule: ABC transporter ATPase subunit (ABCS) [22], [23], [24]
Molecule Alteration Expression
Up-regulation
Resistant Disease Bacterial infection [ICD-11: 1A00-1C4Z]
Experimental Note Identified from the Human Clinical Data
In Vitro Model Enterococcus faecalis isolates 1351
Experiment for
Molecule Alteration
Whole genome sequence assay
Experiment for
Drug Resistance
Broth microdilution method assay
Mechanism Description Multidrug efflux pump extraction, purification, and sequencing showed the distribution of mefA and msrA/msrB efflux pumps.
Key Molecule: Putative ABC transporter ATP-binding component (OTRC) [25]
Molecule Alteration Expression
Up-regulation
Resistant Disease Bacterial infection [ICD-11: 1A00-1C4Z]
Experimental Note Identified from the Human Clinical Data
In Vitro Model Escherichia coli BL21 (DE3) 469008
Escherichia coli 668369
Escherichia coli ET12567 (pUZ8002) 562
Streptomyces rimosus M4018 1927
Streptomyces rimosus SR16 1927
Experiment for
Molecule Alteration
Whole genome sequence assay; Allelic frequency measurement assay
Experiment for
Drug Resistance
MIC assay
Mechanism Description OtrC is a multidrug resistance protein based on an ATP hydrolysis-dependent active efflux mechanism.OtrC is a multidrug resistance protein based on an ATP hydrolysis-dependent active efflux mechanism.
Escherichia coli intestinal infection [ICD-11: 1A03]
Click to Show/Hide
Drug Resistance Data Categorized by Their Corresponding Mechanisms
       Drug Inactivation by Structure Modification (DISM) Click to Show/Hide
Key Molecule: Beta-lactamase (BLA) [26]
Molecule Alteration Expression
Inherence
Resistant Disease Escherichia coli infection [ICD-11: 1A03.0]
Experimental Note Identified from the Human Clinical Data
In Vitro Model Escherichia coli Co227 562
Escherichia coli Co228 562
Escherichia coli Co356 562
Experiment for
Molecule Alteration
PCR; PCR-restriction fragment length polymorphism analysis; Sequencing assay
Experiment for
Drug Resistance
Agar dilution method assay
Mechanism Description Multiple-antibiotic-resistant phenotype is associated with gene mutation and mar locus regulation.
Key Molecule: Beta-lactamase (BLA) [26]
Molecule Alteration Expression
Inherence
Resistant Disease Escherichia coli infection [ICD-11: 1A03.0]
Experimental Note Identified from the Human Clinical Data
In Vitro Model Escherichia coli Co227 562
Escherichia coli Co228 562
Escherichia coli Co356 562
Experiment for
Molecule Alteration
PCR; PCR-restriction fragment length polymorphism analysis; Sequencing assay
Experiment for
Drug Resistance
Agar dilution method assay
Mechanism Description Multiple-antibiotic-resistant phenotype is associated with gene mutation and mar locus regulation.
Key Molecule: Metallo-beta-lactamase (VIM1) [3]
Molecule Alteration Expression
Acquired
Resistant Disease Escherichia coli infection [ICD-11: 1A03.0]
Experimental Note Identified from the Human Clinical Data
In Vitro Model Escherichia coli 668369
Achromobacter xylosoxydans subsp. denitrificans AX-22 85698
Escherichia coli MkD-135 562
Pseudomonas aeruginosa 10145/3 287
Experiment for
Molecule Alteration
DNA extraction and Sequencing assay
Experiment for
Drug Resistance
Macrodilution broth method assay
Mechanism Description Electroporation of Escherichia coli DH5alpha with the purified plasmid preparation yielded ampicillin-resistant transformants which contained a plasmid apparently identical to pAX22 (data not shown). DH5alpha(pAX22) produced carbapenemase activity (specific activity of crude extract, 202 +/- 14 U/mg of protein) and, compared to DH5alpha, exhibited a decreased susceptibility to several Beta-lactams.
Key Molecule: Beta-lactamase (BLA) [12]
Molecule Alteration Expression
Inherence
Resistant Disease Escherichia coli infection [ICD-11: 1A03.0]
Experimental Note Discovered Using In-vivo Testing Model
In Vitro Model Escherichia coli 668369
Escherichia coli strain HB101 634468
Escherichia coli strain JC2926 562
Experiment for
Molecule Alteration
DNA sequencing assay
Mechanism Description SHV Beta-lactamases confer resistance to a broad spectrum of Beta-lactam antibiotics and are of great therapeutic concern for infections caused by many species of the family Enterobacteriaceae. SHV-1, the original member of the SHV Beta-lactamase family, is present in most strains of Klebsiella pneumoniae and may be either chromosomally or plasmid mediated. A plasmid-mediated SHV-1 is also commonly found in Escherichia coli and is seen in other genera as well.
Key Molecule: Aminoglycoside 3'-phosphotransferase (A3AP) [27]
Molecule Alteration Expression
Acquired
Resistant Disease Escherichia coli infection [ICD-11: 1A03.0]
Experimental Note Identified from the Human Clinical Data
In Vitro Model Escherichia coli HB101 634468
Escherichia coli strain JM103 83333
Bacillus circulans strain 1397
Streptomyces lividans strain 66 1200984
Streptomyces lividans strain M180 1916
Experiment for
Molecule Alteration
DNA sequencing assay
Experiment for
Drug Resistance
Semi-quantitative phosphocellulose-paper binding assay method assay
Mechanism Description The previous demonstration that the APH gene of B. circulans could be expressed in E.coli. These contained a 5.5kb Hind3-digest insert (pCH4) or a 2.7kb Sal1-digest insert (pCH5) at the corresponding site in pBR322. Both these derivatives expressed ampicillin and ribostamycin resistance in E.coli.
Non-tuberculous mycobacteria infection [ICD-11: 1B21]
Click to Show/Hide
Drug Resistance Data Categorized by Their Corresponding Mechanisms
       Drug Inactivation by Structure Modification (DISM) Click to Show/Hide
Key Molecule: OXA-23 carbapenemase (BLA OXA-23) [28]
Molecule Alteration Expression
Up-regulation
Resistant Disease Cutaneous bacterial infection [ICD-11: 1B21.4]
Experimental Note Identified from the Human Clinical Data
In Vitro Model Acinetobacter baumannii isolates 470
Experiment for
Molecule Alteration
qRT-PCR
Experiment for
Drug Resistance
Broth microdilution method assay; Agar dilution method assay
Mechanism Description The isolate was resistant to antibiotics other than ampicillin-sulbactam and colistin, suggesting drug resistance due to carbapenemase production by OXA-23.carbapenem resistance in the isolated carbapenem-resistant A. baumannii strain was at least partially conferred by bla OXA-23-like carbapenemase.
Tissue pyogenic bacterial infection [ICD-11: 1B7Y]
Click to Show/Hide
Drug Resistance Data Categorized by Their Corresponding Mechanisms
       Irregularity in Drug Uptake and Drug Efflux (IDUE) Click to Show/Hide
Key Molecule: Multidrug resistance protein 1 (ABCB1) [10]
Molecule Alteration Expression
Up-regulation
Resistant Disease Staphylococcus infection [ICD-11: 1B7Y.3]
Experimental Note Identified from the Human Clinical Data
In Vitro Model Pseudomonas aeruginosa isolates 287
Staphylococcus aureus isolates 1280
Klebsiella pneumoniae isolates 573
Acinetobacter isolates 469
Enterobacter cloacae isolates 550
Experiment for
Drug Resistance
Disk diffusion method assay
Mechanism Description Up-regulation of P-glycoprotein led to ampicillin resistance in the staphylococcus infection.
ICD-13: Digestive system diseases
Click to Show/Hide the Resistance Disease of This Class
Periodontal disease [ICD-11: DA0C]
Click to Show/Hide
Drug Resistance Data Categorized by Their Corresponding Mechanisms
       Drug Inactivation by Structure Modification (DISM) Click to Show/Hide
Key Molecule: Beta-lactamase (Q9X4S7) [13]
Molecule Alteration Expression
Inherence
Resistant Disease Chronic periodontitis [ICD-11: DA0C.Y]
Experimental Note Discovered Using In-vivo Testing Model
In Vitro Model Prevotella nigrescens strain 28133
Experiment for
Molecule Alteration
PCR
Experiment for
Drug Resistance
Disc diffusion test
Mechanism Description Seventy five percent of patients carried two species of beta-lactamase-producing anaerobic bacteria that comprised 9.4% of the total number of cultivable bacteria. Fifty one percent of beta-lactamase-producing strains mainly Prevotella, Porphyromonas, and Bacteroides carried the cfxA gene, whereas none of them carried blaTEM. Further characterization of the cfxA gene showed that 76.7% of these strains carried the cfxA2 gene, 14% carried cfxA3, and 9.3% carried cfxA6. The cfxA6 gene was present in three Prevotella spp. and in one Porphyromonas spp. Strains containing cfxA genes (56%) were resistant to the beta-lactam antibiotics.
Key Molecule: Beta-lactamase (Q9X4S7) [13]
Molecule Alteration Expression
Inherence
Resistant Disease Chronic periodontitis [ICD-11: DA0C.Y]
Experimental Note Discovered Using In-vivo Testing Model
In Vitro Model Porphyromonas gingivalis strain 837
Experiment for
Molecule Alteration
PCR
Experiment for
Drug Resistance
Disc diffusion test
Mechanism Description Seventy five percent of patients carried two species of beta-lactamase-producing anaerobic bacteria that comprised 9.4% of the total number of cultivable bacteria. Fifty one percent of beta-lactamase-producing strains mainly Prevotella, Porphyromonas, and Bacteroides carried the cfxA gene, whereas none of them carried blaTEM. Further characterization of the cfxA gene showed that 76.7% of these strains carried the cfxA2 gene, 14% carried cfxA3, and 9.3% carried cfxA6. The cfxA6 gene was present in three Prevotella spp. and in one Porphyromonas spp. Strains containing cfxA genes (56%) were resistant to the beta-lactam antibiotics.
ICD-16: Genitourinary system diseases
Click to Show/Hide the Resistance Disease of This Class
Urinary tract infection [ICD-11: GC08]
Click to Show/Hide
Drug Resistance Data Categorized by Their Corresponding Mechanisms
       Drug Inactivation by Structure Modification (DISM) Click to Show/Hide
Key Molecule: Aminoglycoside (3'') (9) adenylyltransferase (AADA) [11]
Molecule Alteration Expression
Inherence
Resistant Disease Urinary tract infection [ICD-11: GC08.1]
Experimental Note Identified from the Human Clinical Data
In Vitro Model Escherichia coli serogroup O11 1095705
Escherichia coli serogroup O17 1010800
Escherichia coli serogroup O73 2170725
Escherichia coli serogroup O77 562
Experiment for
Molecule Alteration
PCR amplification and sequence alignments assay
Experiment for
Drug Resistance
Microdilution method assay
Mechanism Description All the UTI outbreak CgA strains in this study contained the same class 1 integron dfrA17-aadA5 gene cassette arrangement with 100% sequence match, suggesting clonal spread of the bacterial strain itself. While aminoglycoside adenyltransferase A (aadA ) and dihydrofolate reductase A (dfrA ), encoding resistance to streptomycin and trimethoprim.
Key Molecule: Aminoglycoside (3'') (9) adenylyltransferase (AADA) [11]
Molecule Alteration Expression
Inherence
Resistant Disease Urinary tract infection [ICD-11: GC08.1]
Experimental Note Identified from the Human Clinical Data
In Vitro Model Escherichia coli serogroup O11 1095705
Escherichia coli serogroup O17 1010800
Escherichia coli serogroup O73 2170725
Escherichia coli serogroup O77 562
Experiment for
Molecule Alteration
PCR amplification and sequence alignments assay
Experiment for
Drug Resistance
Microdilution method assay
Mechanism Description All the UTI outbreak CgA strains in this study contained the same class 1 integron dfrA17-aadA5 gene cassette arrangement with 100% sequence match, suggesting clonal spread of the bacterial strain itself. While aminoglycoside adenyltransferase A (aadA ) and dihydrofolate reductase A (dfrA ), encoding resistance to streptomycin and trimethoprim.
       Unusual Activation of Pro-survival Pathway (UAPP) Click to Show/Hide
Key Molecule: Dihydrofolate reductase (DHFR) [11]
Molecule Alteration Expression
Inherence
Resistant Disease Urinary tract infection [ICD-11: GC08.1]
Experimental Note Identified from the Human Clinical Data
In Vitro Model Escherichia coli serogroup O11 1095705
Escherichia coli serogroup O17 1010800
Escherichia coli serogroup O73 2170725
Escherichia coli serogroup O77 562
Experiment for
Molecule Alteration
PCR amplification and sequence alignments assay
Experiment for
Drug Resistance
Microdilution method assay
Mechanism Description All the UTI outbreak CgA strains in this study contained the same class 1 integron dfrA17-aadA5 gene cassette arrangement with 100% sequence match, suggesting clonal spread of the bacterial strain itself. While aminoglycoside adenyltransferase A (aadA ) and dihydrofolate reductase A (dfrA ), encoding resistance to streptomycin and trimethoprim.
Key Molecule: Dihydrofolate reductase (DHFR) [11]
Molecule Alteration Expression
Inherence
Resistant Disease Urinary tract infection [ICD-11: GC08.1]
Experimental Note Identified from the Human Clinical Data
In Vitro Model Escherichia coli serogroup O11 1095705
Escherichia coli serogroup O17 1010800
Escherichia coli serogroup O73 2170725
Escherichia coli serogroup O77 562
Experiment for
Molecule Alteration
PCR amplification and sequence alignments assay
Experiment for
Drug Resistance
Microdilution method assay
Mechanism Description All the UTI outbreak CgA strains in this study contained the same class 1 integron dfrA17-aadA5 gene cassette arrangement with 100% sequence match, suggesting clonal spread of the bacterial strain itself. While aminoglycoside adenyltransferase A (aadA ) and dihydrofolate reductase A (dfrA ), encoding resistance to streptomycin and trimethoprim.
References
Ref 1 Genetic analysis of the beta-lactamases of Mycobacterium tuberculosis and Mycobacterium smegmatis and susceptibility to beta-lactam antibiotics. Microbiology (Reading). 2005 Feb;151(Pt 2):521-532. doi: 10.1099/mic.0.27629-0.
Ref 2 Purification and properties of the Mycobacterium smegmatis mc(2)155 beta-lactamase. FEMS Microbiol Lett. 1997 Apr 1;149(1):11-5. doi: 10.1016/s0378-1097(97)00041-4.
Ref 3 In70 of plasmid pAX22, a bla(VIM-1)-containing integron carrying a new aminoglycoside phosphotransferase gene cassette. Antimicrob Agents Chemother. 2001 Apr;45(4):1249-53. doi: 10.1128/AAC.45.4.1249-1253.2001.
Ref 4 Occurrence of antibiotic resistance gene cassettes aac(6')-Ib, dfrA5, dfrA12, and ereA2 in class I integrons in non-O1, non-O139 Vibrio cholerae strains in India. Antimicrob Agents Chemother. 2002 Sep;46(9):2948-55. doi: 10.1128/AAC.46.9.2948-2955.2002.
Ref 5 Investigation and analysis of the characteristics and drug sensitivity of bacteria in skin ulcer infections .Chin J Traumatol. 2017 Aug;20(4):194-197. doi: 10.1016/j.cjtee.2016.09.005. Epub 2017 May 24. 10.1016/j.cjtee.2016.09.005
Ref 6 Emerging Gram-positive bacteria and drug resistance in cirrhosis patients with spontaneous bacterial peritonitis: A retrospective studyExp Ther Med. 2019 Jun;17(6):4568-4576. doi: 10.3892/etm.2019.7502. Epub 2019 Apr 18.
Ref 7 Shotgun whole genome sequencing of drug-resistance Streptococcus anginosus strain 47S1 isolated from a patient with pharyngitis in Saudi ArabiaJ Infect Public Health. 2021 Dec;14(12):1740-1749. doi: 10.1016/j.jiph.2021.11.010. Epub 2021 Nov 16.
Ref 8 Analysis of clinical distribution and drug resistance of klebsiella pneumoniae pulmonary infection in patients with hypertensive intra cerebral hemorrhage after minimally invasive surgeryPak J Med Sci. 2022 Jan-Feb;38(1):237-242. doi: 10.12669/pjms.38.1.4439.
Ref 9 Update on Shigella and Nontyphoidal Salmonella Antimicrobial Drug Resistance: Implications on Empirical Treatment of Acute Infectious Diarrhea in CambodiaAntimicrob Agents Chemother. 2021 Oct 18;65(11):e0067121. doi: 10.1128/AAC.00671-21. Epub 2021 Aug 16.
Ref 10 Pathogen characteristics reveal novel antibacterial approaches for interstitial lung disease .Pulm Pharmacol Ther. 2014 Dec;29(2):250-4. doi: 10.1016/j.pupt.2014.03.005. Epub 2014 Apr 1. 10.1016/j.pupt.2014.03.005
Ref 11 Global spread of mobile antimicrobial drug resistance determinants in human and animal Escherichia coli and Salmonella strains causing community-acquired infections. Clin Infect Dis. 2009 Aug 1;49(3):365-71. doi: 10.1086/600301.
Ref 12 Automated thermal cycling is superior to traditional methods for nucleotide sequencing of bla(SHV) genes. Antimicrob Agents Chemother. 1999 Dec;43(12):2960-3. doi: 10.1128/AAC.43.12.2960.
Ref 13 Detection of cfxA2, cfxA3, and cfxA6 genes in beta-lactamase producing oral anaerobes .J Appl Oral Sci. 2016 Apr;24(2):142-7. doi: 10.1590/1678-775720150469. 10.1590/1678-775720150469
Ref 14 Precise insertion of antibiotic resistance determinants into Tn21-like transposons: nucleotide sequence of the OXA-1 beta-lactamase gene. Proc Natl Acad Sci U S A. 1987 Nov;84(21):7378-82. doi: 10.1073/pnas.84.21.7378.
Ref 15 Identifying novel Beta-lactamase substrate activity through in silico prediction of antimicrobial resistance. Microb Genom. 2021 Jan;7(1):mgen000500. doi: 10.1099/mgen.0.000500.
Ref 16 Natural evolution of TEM-1 Beta-lactamase: experimental reconstruction and clinical relevance. FEMS Microbiol Rev. 2010 Nov;34(6):1015-36. doi: 10.1111/j.1574-6976.2010.00222.x.
Ref 17 Nucleotide sequence of the ampicillin resistance gene of Escherichia coli plasmid pBR322. Proc Natl Acad Sci U S A. 1978 Aug;75(8):3737-41. doi: 10.1073/pnas.75.8.3737.
Ref 18 Biochemical characterization of the naturally occurring oxacillinase OXA-50 of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2004 Jun;48(6):2043-8. doi: 10.1128/AAC.48.6.2043-2048.2004.
Ref 19 New aminoglycoside acetyltransferase gene, aac(3)-Id, in a class 1 integron from a multiresistant strain of Vibrio fluvialis isolated from an infant aged 6 months. J Antimicrob Chemother. 2004 Jun;53(6):947-51. doi: 10.1093/jac/dkh221. Epub 2004 Apr 29.
Ref 20 Cefotaxime-resistant Enterobacteriaceae isolates from a hospital in Warsaw, Poland: identification of a new CTX-M-3 cefotaxime-hydrolyzing beta-lactamase that is closely related to the CTX-M-1/MEN-1 enzyme. Antimicrob Agents Chemother. 1998 Apr;42(4):827-32. doi: 10.1128/AAC.42.4.827.
Ref 21 Analysis of a carbapenem-hydrolyzing class A beta-lactamase from Enterobacter cloacae and of its LysR-type regulatory protein. Proc Natl Acad Sci U S A. 1994 Aug 2;91(16):7693-7. doi: 10.1073/pnas.91.16.7693.
Ref 22 Macrolide efflux in Streptococcus pneumoniae is mediated by a dual efflux pump (mel and mef) and is erythromycin inducible. Antimicrob Agents Chemother. 2005 Oct;49(10):4203-9. doi: 10.1128/AAC.49.10.4203-4209.2005.
Ref 23 First report of mefA and msrA/msrB multidrug efflux pumps associated with blaTEM-1 Beta-lactamase in Enterococcus faecalis. Int J Infect Dis. 2012 Feb;16(2):e104-9. doi: 10.1016/j.ijid.2011.09.024. Epub 2011 Dec 1.
Ref 24 Comparative genomics of IncL/M-type plasmids: evolution by acquisition of resistance genes and insertion sequences. Antimicrob Agents Chemother. 2013 Jan;57(1):674-6. doi: 10.1128/AAC.01086-12. Epub 2012 Oct 31.
Ref 25 Molecular cloning and functional characterization of an ATP-binding cassette transporter OtrC from Streptomyces rimosus. BMC Biotechnol. 2012 Aug 20;12:52. doi: 10.1186/1472-6750-12-52.
Ref 26 Mechanisms of resistance in multiple-antibiotic-resistant Escherichia coli strains of human, animal, and food origins. Antimicrob Agents Chemother. 2004 Oct;48(10):3996-4001. doi: 10.1128/AAC.48.10.3996-4001.2004.
Ref 27 Sequence and interspecies transfer of an aminoglycoside phosphotransferase gene (APH) of Bacillus circulans. Self-defence mechanism in antibiotic-producing organisms. Biochem J. 1986 Jan 15;233(2):383-93. doi: 10.1042/bj2330383.
Ref 28 Daptomycin .J Antimicrob Chemother. 2018 Jan 1;73(1):1-11. doi: 10.1093/jac/dkx349. 10.1093/jac/dkx349

If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Zhang.